PKIB,癌症治疗的新目标
Anna Musket1,2, Jonathan P Moorman1,2,3, Jinyu Zhang1,2
1Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.
International journal of molecular sciences
|May 11, 2024
概括
蛋白激酶A抑制剂β (PKIB) 影响癌细胞的行为和预后. 对PKIB的进一步研究.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 细胞信号传输 细胞信号传输
背景情况:
- 蛋白激酶A (PKA) 是一个关键的cAMP依赖酶,调节细胞过程.
- 蛋白激酶抑制剂β (PKIB) 是一种内源性PKA抑制剂,其确切作用仍在研究中.
- PKIB表达与荷尔蒙信号相关,与癌症患者的预后有负相关.
研究的目的:
- 审查目前关于PKIB的文献,重点关注其在癌症发展中的作用.
- 探索PKIB作为瘤学治疗点的潜力.
- 通过转录调节和AKT信号传递来总结PKIB对癌细胞行为的影响.
主要方法:
- 对PKIB现有研究的文献综述.
- 对影响PKIB表达的基因调节和激素信号通路的分析.
- 检查PKIB在调节癌细胞功能的机制.
主要成果:
- 增加PKIB表达与癌症患者预后较差有关.
- 通过核转录调制,PKIB会影响癌细胞的行为.
- PKIB调节瘤性AKT信号通路,有助于癌症的进展.
结论:
- PKIB具有致癌潜力,在各种癌症中发挥着重要作用.
- 了解PKIB的功能对于开发新型癌症疗法至关重要.
- 需要进一步的研究,以充分阐明PKIB在癌症和非癌症疾病中的作用.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


